Conclusions: Our data suggests that TAVI may be a viable alternative to conventional surgical aortic valve replacement in this high risk cohort of patients. doi:10.1016/j.hlc.2011.05.379 377 Transcatheter Aortic Valve Implantation (TAVI). Can We Afford Not to be Involved? S. Pasupati 1,∗, G. Devlin1, M. Liang1, D. Kelly 1, R. Fisher 1, N. Kejriwal 2, A. El-Gamel 2 1Department of Cardiology, Waikato Hospital, Hamilton, New Zealand 2 Department of Cardiothoracic Surgery, Waikato Hospital, Hamilton, New Zealand Background: Transcatheter aortic valves have been implanted inNewZealand sinceAugust 2008.Wedescribe our experience with cost-effective analysis. Methods: TAVI has been implanted for severe, symptomatic aortic stenosis (AS) in patients considered high risk for traditional surgical valve replacement using Medtronic CoreValveTM (MCV) and Edwards SapienTM (ESV) valve via trans-arterial or trans-apical access. All patients with severe AS over a year period who received surgical aortic valve replacement (SAVR) in our institution were used for cost-effective analysis. This included t t a